MagneGas Signs Definitive Agreements for $2.65 Million Equipment Sale to German Company; Largest Single Sale in Company History

TAMPA, Florida, January 5, 2017 /PRNewswire/ —

MagneGas Corporation (“MagneGas” or the “Company”) (MNGA) a leading technology Company that counts among its inventions a patented process that converts renewable and waste liquids into MagneGas2® fuel, announced today that it has entered into its largest equipment sale to date with the signature of definitive agreements (“Agreements”) to manufacture and deliver certain equipment and supplies to a company based in Germany. MagneGas will receive $2.65 million for its proprietary Gasification and Sterilization systems and will supply MagnesGas2® fuel and cylinders.

Under the terms of the Agreements, MagneGas will manufacture and deliver: 1) A 300KW stationary Gasification system; 2) A 100KW mobile Sterilization system; 3) 250 cylinders full of MagneGas2®; and 4) 50 MagneGas regulators.  A deposit of $25,000 has been received, with progress payments totaling $2.625 million to be paid over the course of the manufacturing and delivery of the various systems.  The first payment of $1.35 million is due in 90 days with progress payments due thereafter with set construction and delivery milestones.  In addition, the German company has indicated an interest in negotiating to purchase several additional systems for multiple markets.  

The German company has indicated they will initially utilize the Gasification system to produce MagneGas2® fuel to sell into the German market with the potential of other markets coming online soon after.  The Sterilization system is expected be used for demonstrations and small service contracts with the goal of entering the agriculture and municipal wastewater treatment markets in Germany.

Ermanno Santilli, CEO of MagneGas Corporation stated: “We are thrilled that our original LOI progressed so quickly to definitive agreements.  We believe MagneGas2® fits very well into the European markets that have been moving towards clean and renewable fuel alternatives.  This is the largest sale in the history of MagneGas and our first sale in Europe.  We are looking forward to 2017 and believe this is a great start.”

The MagneGas IR App is now available for free in Apple’s App Store for the iPhone or iPad and at Google Play for Android mobile devices.

To be added to the MagneGas investor email list, please email with MNGA in the subject line.

About MagneGas Corporation  

MagneGas® Corporation (MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels. These fuels can be used as an alternative to natural gas or for metal cutting. The Company’s testing has shown that its metal cutting fuel “MagneGas2®” is faster, cleaner and more productive than other alternatives on the market. It is also cost effective and safe to use with little changeover costs.  The Company currently sells MagneGas2® into the metal working market as a replacement to acetylene.

The Company also sells equipment for the sterilization of bio-contaminated liquid waste for various industrial and agricultural markets. In addition, the Company is developing a variety of ancillary uses for MagneGas® fuels utilizing its high flame temperature for co-combustion of hydrocarbon fuels and other advanced applications.  For more information on MagneGas®, please visit the Company’s website at

The Company distributes MagneGas2® through Independent Distributors in the U.S and through its wholly owned distributor, ESSI (Equipment Sales and Services, Inc.). ESSI has four locations in Florida and distributes MagneGas2®, industrial gases and welding supplies. For more information on ESSI, please visit the company’s website at


This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using virgin vegetable oil to produce fuel while it configures its systems to properly process waste within local regulatory requirements.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at

Investor Contacts:

KCSA Strategic Communications
Philip Carlson
+1-212-896-1233 /

SOURCE MagneGas Corporation

Neurelis Announces Finalization Of Series B Financing

SAN DIEGO, Jan. 5, 2017 /PRNewswire/ — Neurelis, Inc. today announced that it has finalized a Series B financing round led by HBM Healthcare Investments. In addition, LYZZ Capital, which led the Series A funding for Neurelis, has participated in the Series B round.  The company will utilize the funds to complete clinical trials for NRL-1 (intranasal diazepam), prepare the planned New Drug Application (NDA) for submission to the U.S. Food and Drug Administration (FDA), and begin preparations for the commercial launch of the product.  NRL-1 is being developed for pediatric, adolescent, and adult epilepsy patients who experience acute repetitive or cluster seizures.  The program is in the final phase of clinical development and the NDA application is planned for submission in 2018. 

“We are very excited to have completed the company’s Series B financing round,” said Craig C. Chambliss, President and Chief Executive Officer of Neurelis. “We are pleased to bring an outstanding investor in HBM Healthcare to the Neurelis team and greatly appreciate the continued confidence that LYZZ Capital has shown with their full participation in this financing.  We can now complete the clinical development work for NRL-1, assemble our NDA submission, and prepare for the commercialization of this important Orphan Drug product for the epilepsy community.”

On Wednesday, the company announced that that the FDA has designated NRL-1 as a Fast Track Development program.  The Company had previously received Orphan Drug designation for the NRL-1 in November of 2015.  There is a significant unmet clinical need that exists for epilepsy patients suffering from acute repetitive or cluster seizures. The only approved product currently available, Diastat®, requires rectal administration.  This can be an issue – especially with adolescent and adult patients.  NRL-1 was developed as a unique formulation which allows delivery of a therapeutic dose of diazepam via a well-tolerated nasal spray in order to provide rapid treatment of these seizures where they occur — at home, work, school or elsewhere.

About NRL-1

NRL-1 (intranasal diazepam) is a proprietary patented formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures.   NRL-1 has been granted Orphan Drug and Fast Track Designations by the FDA.  In clinical trials, NRL-1 has demonstrated high bioavailability, low variability from dose to dose, and was well-tolerated. 

Acute Repetitive/Cluster Seizures

There are over 2.7 million people with epilepsy in the United States with approximately 200,000 new patients diagnosed each year.  It is estimated that between 30% and 40% of these patients are uncontrolled on oral therapy and are at-risk for acute breakthrough seizures.  Acute repetitive or cluster seizures may occur over a number of hours or days and can include any seizure type.  Studies have shown that prolonged or repetitive seizures can cause neurological damage and dramatically increase the risk of changes in neuropsychological function or even death.

About Neurelis

Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market.  Neurelis is leveraging its expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates, such as NRL-1 for the treatment of acute repetitive or cluster seizures, to address significant unmet medical needs.  For more information, go to

For More Information:
Mark Leonard 

SOURCE Neurelis, Inc.

Inaugural Toyota Material Handling North America University Research Program Funds Top Research Proposals

COLUMBUS, Ind., Jan. 5, 2017 /PRNewswire/ — In July 2016, Toyota Material Handling North America (TMHNA) announced the premiere of the TMHNA University Research Program, a sponsored research program created to drive the next generation of technologies for the entire supply chain, logistics and material handling industry. The program received outstanding response, with application proposals from leading universities across North America.

After evaluating a competitive set of applications, TMHNA has selected three proposals to award funding:

“These universities have presented projects that can help foster innovation for the growth of our industry and the warehouses of the future,” said Brett Wood, president and chief executive officer for Toyota Material Handling North America. “We look forward to seeing what this funding and collaboration will allow these universities to accomplish, and the positive impacts their research could have on driving the future of our industry.”

For more information about the TMHNA University Research Program, visit

About Toyota Material Handling North America. (TMHNA)
Toyota Material Handling North America (TMHNA), the industry leader in forklift sales, is composed of three main group companies: Toyota Material Handling U.S.A., Inc.; Toyota Industrial Equipment Mfg., Inc.; and The Raymond Corporation. One in three forklifts sold in North America is either a Toyota or Raymond product. With more than 1.5 million square feet of manufacturing space, TMHNA is composed of three manufacturing plant locations (Columbus, Indiana; Greene, New York; and Muscatine, Iowa) that produce 1,500 forklifts per week on average, with parts distribution locations in Syracuse, New York, and Columbus, Indiana, with more than 3 million service parts available. With an annual revenue of approximately $3 billion, TMHNA has more than 8,000 people and more than 300 dealer locations to support Toyota and Raymond customers throughout North America.   

© Copyright 2016 Toyota Material Handling North America, Toyota Material Handling U.S.A., Inc.; Toyota Industrial Equipment Mfg., The Raymond Corporation, University Research Program


SOURCE Toyota Material Handling North America (TMHNA)

Police Associations Call On House Speaker Paul Ryan to Remove “Art” Depicting Cops as Pigs from Nation's Capitol

LOS ANGELES, Jan. 5, 2017 /PRNewswire/ — A letter was jointly sent to House of Representatives Speaker Paul Ryan by the Presidents of the Los Angeles Police Protective League (LAPPL), the Sergeants Benevolent Association of New York, and the San Francisco, Oakland and San Jose Police Officers Associations, strongly urging him to exert the extraordinary power he possesses to remove from our nation’s Capitol a piece of “art” that depicts police officers as Pigs intent on harming the very communities we serve.

This “art” was selected by a Missouri Congressman as part of an annual congressional art competition with little regard to the negative and offensive portrayal of law enforcement.

The letter states:

The associations above represent over 27,000 police officers, sergeants, and other ranks.  You can view the letter here and the “art” here

About the LAPPLFormed in 1923, the Los Angeles Police Protective League (LAPPL) represents the more than 9,900 dedicated and professional sworn members of the Los Angeles Police Department. The LAPPL serves to advance the interests of LAPD officers through legislative and legal advocacy, political action and education. The LAPPL can be found on the Web at 

SOURCE Los Angeles Police Protective League

BioHiTech Global Names David Fenton as Vice President, National Accounts

CHESTNUT RIDGE, N.Y., Jan. 5, 2017 /PRNewswire/ — BioHiTech Global, Inc. (“BioHiTech” or the “Company”) (OTCQB: BHTG), a green technology company that develops and deploys cost effective sustainable waste management solutions, today announced the appointment of David Fenton as Vice President, National Accounts. Fenton brings nearly three-decades of experience in the waste management industry with a proven track record of driving sales growth with large nationwide customers.  His new role at BioHiTech, will focus on expanding the company’s national account program to increase brand penetration across the United States.

“We are thrilled to have David join the BioHiTech team to spearhead our national account program,” said Frank E. Celli, CEO of BioHiTech Global. “David brings a tremendous amount of experience in all aspects of the waste management vertical, along with proven expertise in establishing and developing large scale customer relationships.  His experience, industry relationships and sales leadership will be a driving force at BioHiTech as we continue to roll out our innovative and cost effective sustainable solutions.  We look forward to working with David as we expand BioHiTech as a nationwide leader in sustainable waste management.”

Prior to joining BioHiTech, Fenton spent nearly five years with Quest Resource Management Group, one of the first companies to provide their clients with a nationwide solution for food waste. Prior to Quest he spent six years with Oakleaf Waste Management, previously an industry leading third party waste and recycling solution provider. Fenton has also held numerous leadership roles in the waste management industry throughout his distinguished career. During his career, David executed or participated in, nearly $700 million dollars of contracted national account revenue generated from clients such as Kroger, Ahold Delhaize, Sprouts, AMC Theaters, PetSmart, and NPC International, which operates more than 1,400 Quick Service restaurant locations throughout the United States. 

About BioHiTech Global
BioHiTech Global (OTCQB: BHTG), “The Company” headquartered in Chestnut Ridge NY, develops and deploys innovative and disruptive waste management technologies. The combined offerings of BioHiTech Global offer our customers a full suite of technology based disposal options capable of having a significant impact on waste generation while providing a true zero landfill environment. With options for both on and off site biological treatment of waste, BioHiTech Global is a leader in zero waste solutions for businesses and municipalities.  For more information, please visit

Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission (“SEC”). There may be other factors not mentioned above or included in the BioHiTech’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
Marketing Director
Direct: 845-262-1081

SOURCE BioHiTech Global, Inc.

Deloitte CFO Signals™ Survey: All Eyes on Next US Administration; Majority Expect Less Congressional Gridlock and Substantial Policy Changes

NEW YORK, Jan. 5, 2017 /PRNewswire/ — Deloitte’s fourth quarter (4Q 2016) CFO Signals survey, which opened the day after the election on Nov. 9, 2016, reveals that all eyes are on the next U.S. administration, with 73 percent of surveyed chief financial officers  expecting less congressional gridlock. Additionally, CFOs generally anticipate substantial policy changes to take place in the next four years in the areas of taxes, repatriation of cash to the U.S., infrastructure investments, health care and immigration:

By contrast, less than 10 percent of the surveyed CFOs predict Congress will pass trade deals with either Europe or Asia respectively.

“CFOs appear to be anticipating substantial changes in policy which will certainly affect their companies. As the new administration’s agenda unfolds and CFOs gain more clarity, it will be interesting to see how CFOs’ optimism and expectations change,” said Sandy Cockrell, national managing partner of the U.S. CFO Program, Deloitte LLP. “For example, despite appearing to be fairly bullish on North America’s economy—and U.S. CFOs indicating higher optimism about their own companies’ prospects than in the last two years—there are concerns about topics, such as tax uncertainty and the possibility of a rising national debt.”

This quarter reveals a sharp contrast between rising optimism regarding own company prospects and all four business outlook metrics tracked by the CFO Signals survey for 27 consecutive quarters. Net optimism in 4Q 2016 remains strong at +23.4, and 43 percent of CFOs express rising optimism about their own companies’ prospects, up from 35 percent last quarter. Net optimism for the U.S. also rose sharply from last quarter’s +16.0 to +34.0 this quarter.

On the other hand, CFO expectations for growth in revenue, earnings, capital spending and domestic hiring all remain near their survey lows.

In particular, U.S. CFOs’ expectations for revenue, earnings and capital investment all came in near historic survey lows.  

Each quarter, CFOs are also asked which risks they regard as most worrisome. The top three external risks CFOs cited this quarter are: 1) uncertainty about the new administration; 2) a tie between the impact of protectionism on global trade and global growth/recession; and 3) new/burdensome regulation. Like last quarter, securing qualified talent tops the list of internal risks cited, followed by execution of strategies and plans in second place, and retaining key employees and controlling costs and expenses, tied for third.

When asked about expectations for the macroeconomic environment in 2017, 58 percent of U.S. CFOs agree that the U.S. economy will improve over the next year, but only 14 percent of Canadian CFOs expect their economy to improve. No Mexican CFOs expect better conditions for Mexico’s economy.

In their assessment of broader regional economies, 43 percent of CFOs say current conditions in North America’s economy are good compared to 46 percent last quarter, while 58 percent expect better conditions in a year, up from 37 percent last quarter. Eight percent of CFOs perceive Europe’s current economy as good, up from 4 percent last quarter; 13 percent expect better conditions a year from now, slightly higher than last quarter’s 10 percent. Perceptions of China’s economy improved with 24 percent of CFOs describing it as good, up from 10 percent last quarter, and 17 percent expecting conditions to improve, up from 14 percent last quarter.

When asked about their industry expectations in 2017, surveyed CFOs are mostly optimistic about their industries’ growth, with 54 percent expecting their revenue to grow, and more than half anticipating technology advances to be a major factor in changing both industry products and services and how their industry operates. Sixty-six percent of CFOs expect that industry-skilled talent will be difficult to acquire, and 67 percent believe wage increases will be necessary to secure and retain highly skilled workers.

“This quarter’s findings show high industry and country variability in sentiment and expectations,” commented Greg Dickinson, managing director, Deloitte LLP, who leads the North American CFO Signals survey. “But expectations were very diverse even within particular regions and industries, which seems to indicate inconsistent ideas about how the new administration will proceed and how worldwide markets will respond.”

Additional findings from the Deloitte 4Q 2016 CFO Signals survey include:

“CFOs’ views about the changing economic environment are similar to those of economists, as reflected in Deloitte’s recent US Economic Forecast,” says Danny Bachman, senior U.S. economist, Deloitte Services LP. “The unexpected results of the presidential election have introduced greater uncertainty about policy in areas such as trade, infrastructure spending, taxes and regulation – with an unusually wide range of possible impacts for business.”

Deloitte’s fourth-quarter 2016 CFO Signal’s survey also provides CFOs’ responses on business focus priorities, expectations for capital, strategy and leadership, and more. To download a copy of the survey, please visit:

About The Deloitte CFO Signals survey
Each quarter, CFO Signals tracks the thinking and actions of CFOs representing many of North America’s largest and most influential organizations. This report summarizes CFOs’ opinions in four areas: business environment, company priorities and expectations, finance priorities and CFOs’ personal priorities.

The Deloitte CFO Signals survey for the fourth quarter of 2016 was conducted during the two-week period opening Nov. 9 and ending Nov. 23, 2016. A total of 137 CFOs responded during this time. Seventy-two percent of respondents are from public companies, and 84 percent are from companies with more than $1 billion in annual revenue. For more information, please see the report.

For more information about Deloitte’s CFO Signals, or to inquire about participating in the survey, please contact

About Deloitte’s CFO Program
The CFO Program brings together a multidisciplinary team of Deloitte leaders and subject matter specialists to help CFOs stay ahead in the face of growing challenges and demands. The program harnesses our organization’s broad capabilities to deliver forward thinking and fresh insights for every stage of a CFO’s career—helping CFOs manage the complexities of their roles, tackle their organization’s most compelling challenges and adapt to strategic shifts in the market. For more information about Deloitte’s CFO Program, please contact or visit

As used in this document, “Deloitte” means Deloitte LLP and its subsidiaries. Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.


SOURCE Deloitte

SKYGEN USA Announces Major Accomplishments in 2016, Releases 2017 Predictions

MEQUON, Wis., Jan. 5, 2017 /PRNewswire/ — SKYGEN USA, a collection of 21st century benefit management solution companies, today announced that 2016 was a watershed year for the organization both in terms of sales and the introduction of several new innovations in the way it serves the $779 billion health and medical insurance industry.  The organization currently partners with clients operating in more than 100 markets serving 28 million member lives on its own technology platform and 11 million member lives through its outsourcing solutions.

SKYGEN USA’s year-over-year revenue grew by 24 percent in 2016.  This increase was driven primarily by SKYGEN USA’s aggressive approach to delivering 21st century technology and benefit management solutions that solve the challenges of today’s commercial and government payers as well as healthcare providers and the members/patients they serve.

“Many health insurance payers’ core technologies are now well over 30 years old,” said Craig Kasten, chairman and co-founder of SKYGEN USA. “They were implemented before smartphones and tablets were on the drawing board, and even before computers became a fixture in most homes and businesses. SKYGEN USA is filling gaps for these organizations by bringing modern technologies as well as in-depth benefit management expertise to help them compete in this very different world, and transform themselves into 21st century cyber benefit organizations.”

The focus on defining what is required for payers to become cyber benefits organizations was a key initiative for SKYGEN USA in 2016. A cyber benefits organization is one that transforms the current health benefit landscape by offering an information-rich environment connecting all patrons while delivering benefits faster and at substantially lower costs than traditional approaches.  While appropriate for all types of payers, managed care organizations (MCOs) for government programs are likely to be among the early adopters to seize the opportunities for improvement cyber benefits bring.  MCOs are under increasing pressure to reduce costs and improve efficiency so more benefits can be delivered to more members without an increase in taxpayer funding.

The year 2016 saw major changes in SKYGEN USA’s internal structure that were put in place to enhance its service to clients. One of the most significant was the building out of SKYGEN USA’s Legal and Compliance practice. Steven J. Berryman was hired as chief legal officer to lead the practice, which will be charged with helping clients navigate the increasingly complex regulatory environment.

Additional 2016 highlights include:

In keeping with SKYGEN USA’s focus on helping payers prepare for the challenges of the future as well as the present, the company also released its predictions around where commercial and government-based health, dental, and vision insurance is headed in 2017:

“Today there is even more uncertainty in an already volatile health insurance industry,” said Greg Borca, co-founder and owner of SKYGEN USA. “It points to the need for payers to have the maximum flexibility in their technology as well as benefit design in order to react quickly to minimize risk and take advantage of market opportunities. The organization we have built with SKYGEN USA, and the organization we are continuing to build through our latest innovations, has the knowledge and capacity to lead payers through these turbulent times and help them thrive. No matter what changes may occur, we are confident that 2017 will be another outstanding year for our clients and our business.”

Tweet This: .@SKYGENUSA recaps 2016 success, offers #2017predictions. #cyberbenefits #healthinsurance

SKYGEN USA is a collection of benefit solution companies that brings together a distinguished mix of next-generation benefit management and technology tools for healthcare organizations. Business units under the SKYGEN USA brand include Wonderbox Technologies, Scion Dental, Vestica Healthcare, American Therapy Administrators, Ocular Benefits and now, Hylis Pharmacy Solutions. The joining of these respected organizations under the SKYGEN USA umbrella enables them to drive process improvements and dramatically reduce the cost of delivering benefits in an advancing healthcare economy. Payers may select the comprehensive solution or individual offerings to fit their requirements. For more information, please go to  

For media inquiries, please contact:
Christine Rudella
Director of Marketing, SKYGEN USA



Trump & US Manufacturing: Industry Thought Leaders to Debate Policy Options

SANTA CLARA, Calif., Jan. 5, 2017 /PRNewswire/ —

In advance of the January 20 inauguration of President-elect Donald Trump, Frost & Sullivan’s Manufacturing Leadership Council (MLC) will host a special virtual debate on the industrial priorities and potential policies for the future of U.S. manufacturing under the new Trump administration.

Join this special session to hear the latest thinking on issues such as advanced technologies, international trade, innovation institutes, regulatory reform, energy and the environment, tax policy and workforce skills.

Thought Leaders:

Attend this panel to:


To request an invite to the panel debate, click here. For press inquiries, email Jaylon Brinkley, Corporate

About the Manufacturing Leadership Council

Founded in 2008, the Manufacturing Leadership Council’s vision is to create and inspire a global community of manufacturing executives who believe in the proposition that manufacturing is the fundamental driver of economic and social prosperity, and that its growth will lead to a better future and a higher standard of living for all people. The MLC’s mission is to inspire manufacturing executives to achieve transformational growth for themselves, their companies, and for the industry at large through enlightened leadership.

The Council focuses on the intersection of advanced technologies and the business, identifying growth and improvement opportunities in the operation, organization and leadership of manufacturing enterprises. In support of this, the Council produces an extensive portfolio of leadership networking, information, and professional development products, programs, and services.

For more information and to join the MLC, please visit

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact Us: Start the discussion

Jaylon Brinkley
Corporate Communications – North America 


SOURCE Frost & Sullivan

El Gift of Life Donor Program supera el record de donación de órganos en Estados Unidos

Es la primera vez que una OPO llega – y supera – los 500 donantes en un año

FILADELFIA, 5 de enero de 2017 /PRNewswire/ — Por noveno año, el Gift of Life Donor Program – la organización de consecución de órganos (OPO) de designación federal sin ánimo de lucro que presta servicio a la mitad oriental de Pennsylvania, el sur de Nueva Jersey y Delaware – es la principal OPO de la nación con su coordinación de éxito de órganos que salvan vidas gracia a 540 donantes de órganos, cuyas generosas otorgaciones consiguieron el transplante de 1.412 órganos. Este hito supone la primera vez que lo logra una OPO gracias a este nivel de donación (más de 500 donantes de órganos) dentro de la historia de la donación de órganos y su transplante. En diciembre, Gift of Life superó además un record nacional mensual, con 62 donantes y 167 órganos trasplantados. La tasa de donación anual de Gift of Life iguala los 49 donantes de órganos por millón de habitantes, clasificándose entre las más elevadas del mundo.

Foto –

Gift of Life además recuperó tejidos de 2.575 donantes en el año 2016. Estas donaciones que salvan vidas y mejoran podrían beneficiar hasta a 100.000 personas, con 1.305 donaciones óseas que mejoran la movilidad, donaciones de piel que curan a los pacientes quemados y donaciones de válvulas cardiacas para reparar los defectos que suponen una amenaza para la vida. Estos donantes proporcionaron además 4.500 córneas que otorgaron el regalo de la vista.

“El año de establecimiento record de Gift of Life solo es posible gracias al desinterés de nuestros donantes y sus familiares. Su fortaleza y compasión en el rostro de la aflicción a menudo no imaginable es aleccionadora”, afirmó Howard M. Nathan, director general y consejero delegado del Gift of Life Donor Program. “Desde el año 1974, hemos abogado a nuestras familias donantes, receptores de trasplantes y miles de personas acerca de la lista de espera de trasplantes. Estamos enormemente agradecidos del talento excepcional y compromiso de nuestros socios hospitalarios – los 15 centros de transplante y 131 hospitales de tratamiento agudo en la región – además de nuestro personal ampliamente capacitado y dedicado que trabaja las 24 horas del día y los 7 días de la semana. Ellos son los que realmente dan a las personas una segunda oportunidad en la vida”.

Muchas de estas historias destacadas se comparten en el Gift of Life’s Second Chance Blog. Los perfiles incluyen un mayor de instituto que vuelve al equipo universitario de fútbol tras un transplante de corazón; una familia que en los más de 30 años desde que su hijo fue donante ha hablado a más de 200.000 estudiantes acerca de la importancia de la donación; y la bendición de un padre de tres niños pequeños que esperó un transplante de riñón que salvara la vida durante más de dos años.

El legado de l donación sigue durante las generaciones, con muchos receptores de trasplantes comenzando en sus propias familias. En el año 2016, el Transplant Pregnancy Registry International (TPR) del Gift of Life Institute celebró su 25 aniversario. Desde 1991, el TPR ha seguido más de 4.000 embarazos después de trasplantes, compartiendo la información con incontables receptores de transplante y tomando decisiones de planificación familiar. El instituto es líder internacional en donación de órganos y tejidos, siguiendo a cerca de 9.000 profesionales procedentes de 37 países desde el año 2004.

La devoción de Gift of Life de cara a la comunidad de los trasplantes incluye además un “home away from home” para pacientes con trasplantes y sus familias. En 2016, el personal y voluntarios de Gift of Life Family House proporcionaron más de 8,605 noches de alojamiento de cuidado, 30.244 comidas y 1.677 transportes hacia y desde los hospitales. Desde su fundación en julio del año 2011, la Family House ha suministrado más de 36.000 alojamientos de noche y servido 141.628 comidas.

Con un avance en marcha en el transplante, la necesidad de las donaciones es cada vez mayor. Aproximadamente 22 personas mueren cada día en Estados Unidos esperando un transplante de órgano. Hay más de 5.600 hombres, mujeres y niños esperando en esta región, y más de 119.000 a nivel nacional. Pese a que el 95% de las personas apoyan la donación, menos de la mitad están registradas, a pesar de que se necesitan menos de 30 segundos de gestión online.   

Acerca del Gift of Life Donor Program: Desde 1974, Gift of Life ha coordinado más de 42.000 trasplantes de órganos y se calcula que 600.000 trasplantes de tejidos. Un donante de órganos puede salvar la vida de hasta 8 personas, mientras que un donante de tejido puede mejorar la vida de hasta 75 personas. One organ donor can save the lives of up to eight people, and a tissue donor can enhance the lives of up to 75 others. Si desea más información o registrarse, visite  

SOURCE Gift of Life Donor Program

Scholastic To Publish Updated Edition of J.K. Rowling's Fantastic Beasts and Where to Find Them by Newt Scamander

NEW YORK, Jan. 5, 2017 /PRNewswire/ — Scholastic Corporation (NASDAQ: SCHL), the global children’s publishing, education and media company, will publish an updated edition of the bestselling and collectible companion book to the Harry Potter books, Fantastic Beasts and Where to Find Them, with a new foreword by J.K. Rowling, writing as Newt Scamander, and a new cover by Headcase Design on March 14, 2017.  The book will be published simultaneously with Bloomsbury UK and the Pottermore eBook edition.

Originally published fifteen years ago, now this book has been revisited by the author to bring the original classic up to date with new content that reflects the exciting developments in J.K. Rowling’s Wizarding World. The book served as the inspiration for the Warner Bros. major motion picture of the same name which marked J.K. Rowling’s screenwriting debut.  Scholastic published the screenplay on November 18, 2016, and the book went to the top of bestseller lists nationwide.

Fantastic Beasts and Where to Find Them has been an approved textbook at Hogwarts School of Witchcraft and Wizardry since its publication. Newt Scamander’s masterpiece has entertained wizarding families through the generations and is an indispensable introduction to the magical beasts of the wizarding world. Scamander’s years of travel and research have created a tome of unparalleled importance. Introducing six new beasts, readers will have fun spotting them among the much-loved favorites. J.K. Rowling’s new introduction, written from the viewpoint of Newt Scamander, offers tantalising hints about the Magizoologist’s adventures and relationships. Some of the beasts will be familiar to readers of the Harry Potter books – the Hippogriff, the Basilisk, the Hungarian Horntail. Others will surprise even the most ardent amateur Magizoologist.

Proceeds from the sale of this edition will go to Comic Relief and J.K. Rowling’s own international charity Lumos, charities which help the world’s most vulnerable children and young people, to help them have a better life.

Scholastic will also release a re-packaged edition of the Hogwarts Library Box Set which includes the new edition of Fantastic Beasts and Where to Find Them as well as Quidditch Through the Ages and The Tales of Beedle the Bard, with a new case by Headcase design.

About J.K. Rowling
J.K. Rowling is the author of the record-breaking, multi-award-winning Harry Potter novels. Loved by fans around the world, the series has sold over 450 million copies, been translated into 79 languages, and made into 8 blockbuster films. She has written three companion volumes in aid of charity: Quidditch Through the Ages and Fantastic Beasts and Where to Find Them (in aid of Comic Relief and Lumos), and The Tales of Beedle the Bard (in aid of Lumos), as well as a film script inspired by Fantastic Beasts and Where to Find Them, her screenwriting debut, and a further extension of the Wizarding World, which was released as a Warner Bros film in November 2016.  In 2012, J.K. Rowling’s digital company Pottermore was launched, where fans can enjoy news, features and articles, as well as original content by J.K. Rowling. Her first novel for adult readers, The Casual Vacancy was published in September 2012 and adapted for TV by the BBC in 2015.  Her crime novels, written under the pseudonym Robert Galbraith, were published in 2013 (The Cuckoo’s Calling), 2014 (The Silkworm) and 2015 (Career of Evil), and are to be adapted for a major new television series for BBC One, produced by Brontë Film and Television.  J.K. Rowling’s 2008 Harvard commencement speech was published in 2015 as an illustrated book, Very Good Lives: The Fringe Benefits of Failure and the Importance of Imagination, and sold in aid of Lumos and university–wide financial aid at Harvard. J.K. Rowling has recently collaborated with writer Jack Thorne and director John Tiffany on the stage play Harry Potter and the Cursed Child Parts One and Two, which is now running at The Palace Theatre in London’s West End. As well as receiving an OBE for services to children’s literature, she has received many awards and honours, including France’s Légion d’Honneur, and the Hans Christian Andersen Award.

About Comic Relief
Since 2001, Quidditch Through the Ages and Fantastic Beasts and Where to Find Them have raised nearly £20 million for Comic Relief- a magic amount of money that is already hard at work changing lives. Money raised through the sale of this new edition will be invested in children and young people around the world, preparing them to be ready for the future – to be safe healthy, educated and empowered. We are particularly interested in helping those children who start their lives in the most difficult circumstances, where there is conflict, violence, neglect or abuse.

About Lumos
Lumos is an international non-profit organisation founded by J.K. Rowling to help the estimated eight million disadvantaged children in orphanages around the world to be returned to their family or placed in a loving family environment.

About Scholastic
Scholastic Corporation (NASDAQ: SCHL) is the world’s largest publisher and distributor of children’s books, a leading provider of print and digital instructional materials for pre-K to grade 12, and a producer of educational and entertaining children’s media. The Company creates quality books and ebooks, print and technology-based learning programs, classroom magazines and other products that, in combination, offer schools customized solutions to support children’s learning both at school and at home. The Company also makes quality, affordable books available to all children through school-based book clubs and book fairs. With a 96 year history of service to schools and families, Scholastic continues to carry out its commitment to “Open a World of Possible” for all children. Learn more at

SOURCE Scholastic Inc.